Skip to main content
Clinical Trials/NCT04107116
NCT04107116
Completed
Not Applicable

Enhancing Community Capacity to Improve Cancer Care Delivery: The Effect of a Lay Health Worker Intervention on Patient-reported Symptoms, Healthcare Use, Total Costs of Care, and End-of-life Care Delivery

Stanford University1 site in 1 country832 target enrollmentNovember 1, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
End of Life
Sponsor
Stanford University
Enrollment
832
Locations
1
Primary Endpoint
Edmonton Symptom Assessment Scale (ESAS) Symptom Screen
Status
Completed
Last Updated
last year

Overview

Brief Summary

Undertreated patient symptoms and resulting acute care use require approaches that improve symptom-burden. Previously a a lay health worker (LHW)-led symptom screening intervention was developed for patients with advanced cancer. This intervention will be expanded to all patients with cancer and the LHW will be trained to refer patients to palliative care and behavioral health. This intervention will evaluate the effect on symptom-burden, survival, healthcare use, and total costs.

Detailed Description

From 11/1/2016 - 9/30/2018, all newly diagnosed Medicare Advantage enrollees with solid or hematologic malignancies were enrolled in the intervention. Outcomes were compared outcomes to patients in the year prior (control arm). The primary outcome was change in symptoms using the Edmonton Symptom Assessment Scale (ESAS) and Personal Health Questionnaire-9 (PHQ-9) at baseline, 6- and 12-months post-enrollment. Secondary outcomes were between-group comparison of survival, 12-month healthcare use and costs.

Registry
clinicaltrials.gov
Start Date
November 1, 2016
End Date
September 30, 2021
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Manali Indravadan Patel

Assistant Professor

Stanford University

Eligibility Criteria

Inclusion Criteria

  • Newly diagnosed with cancer
  • Diagnosis of relapse or progressive disease (any cancer diagnosis) as identified by imaging or biopsy and confirmed by physician.
  • Must be 18 years or older.
  • Must have capacity to verbally consent

Exclusion Criteria

  • Inability to consent to the study due to lack of capacity as documented by the referring physician.

Outcomes

Primary Outcomes

Edmonton Symptom Assessment Scale (ESAS) Symptom Screen

Time Frame: 12 months after patient enrollment

Each patient will receive a quantitative symptom assessment survey (Edmonton Symptom Assessment Scale). Participants rate the intensity of 10 symptoms, each on a 11-point scale (0 to 10); sub-scores are then summed and averaged to create a total symptom score (range: 0 to 10, with 10 corresponding to worst symptom severity).

Personal Health Questionnaire-9 (PHQ-9) Depression Screen

Time Frame: 12 months after patient enrollment

Each patient will receive a Personal Health Questionnaire-9 (PHQ-9) at 12 months. PHQ-9 is measured on a scale of 0-27, where scores of 5, 10, 15, and 20 are cut-points for mild, moderate, moderately severe and severe depression, respectively.

Secondary Outcomes

  • Incidence of Emergency Department Visits Within 12-months After Patient Enrollment (Chart Review)(12 months after patient enrollment)
  • Incidence of Hospitalization Visits Within 12 Months After Patient Enrollment (Chart Review)(12 months after patient enrollment)
  • Number of Patients With a Hospice Consult Within 12-months After Patient Enrollment (Chart Review)(12 months after patient enrollment)
  • Total Health Care Costs (Claims Review)(12 months after patient enrollment)
  • Number of Patients With an Acute Care Facility Death (Chart Review)(30 days prior to death for patients who died at 12-months follow-up)
  • Number of Emergency Department Visit in the Last 30 Days of Life (Chart Review)(30 days prior to death for patients who died at 12-months follow-up)
  • Number of Hospitalization Visits in the Last 30 Days of Life (Chart Review)(30 days prior to death for patients who died at 12-months follow-up)
  • Number of Patients With a Hospice Consult in the Last 30 Days of Life (Chart Review)(30 days prior to death for patients who died at 12-months follow-up)
  • Total Costs of Care (Claims Review)(30 days prior to death for patients who died at 12-months follow-up)

Study Sites (1)

Loading locations...

Similar Trials